TPGS based 99mTc nano radiopharmaceuticals: potential application in breast cancer diagnosis

MARIANO PORTILLO; MORETTON MARCELA; MEDINA VANINA; GIAQUINTA DIEGO; ZUBILLAGA MARCELA; SALGUEIRO MARÍA JIMENA; TESAN FIORELLA; NICOUD MELISA; CHIAPPETTA DIEGO A.

Mar del Plata

Otro; SAIC-SAI-SAFIS 2018; 2018

There is only one useful SPECT radiopharmaceutical (99mTc-sestamibi) for breast cancer diagnosis and follow up and its utility carries with some limitations. Our aim was to evaluate the performance of three micellar 99mTc nano radiopharmaceuticals (i-TPGS; ii- TPGS and Soluplus®; iii- TPGS and Soluplus® with glucose) as radioisotopic imaging probes. Radiolabeling was performed by direct method and a syngeneic orthotopic model of BALB/c mice injectedwith 4T1 cells, was used for scintigraphic diagnosis evaluation with a gamma camera. The uptakes visualized in the images were validated by biological distribution measuring radioactivity accumulation in organs of interesr by Solid Scintillation Counter. Nano radiopharmaceuticals sizes were measured by Dynamic Light Scattering at 25° and 37°C. TPGS and Soluplus® radiopharmaceutical was the only one that allowed scintigraphic visualization of the tumor.Nano radiopharmaceuticals sizes increased at 37°C for system ii and iii (more drastically for the latter). Biological distribution studies showed uptake values that backed up scintigraphic results for eachradiopharmaceutical assayed. In conclusion, mixed system of TPGS and Soluplus® stands as a potential candidate to be used in breast cancer imaging diagnosis